Table 1 Baseline characteristics of trials included in the meta-analysis
Author (Publication Date) | Trial phase | Tumor staging | Interventions | Age (media, years) | follow-up (media,wk) | No. of EP | Jadad score |
|---|---|---|---|---|---|---|---|
Coombes(2007) | Phase 3 trial | Early-stage breast cancer | Exemestane (25 mg/d) |  | 55.7 months | 2320 | 5 |
Velde(2011) | Phase 3 trial | Early-stage breast cancer | Exemestane (25 mg/d) | 64 (35–96) | 61.2 months | 9666 | 5 |
Exemestane (25 mg/d) | |||||||
Arimidex(2008) | Phase 3 trial | Early-stage breast cancer | Anastrozole (1 mg/d) | 64 (9) mean sd | 100 months | 3092 | 4 |
Hiroji(2013) | Phase 3 trial | Advanced-stage breast cancer | Exemestane (25 mg/d) | 64 (9) mean sd | 60.1 months (48.2, NR) | 298 | 3 |
Anastrozole (1 mg/d) | |||||||
Buzdar(1998) | Phase 3 trial | Advanced-stage breast cancer | Anastrozole (1 mg/d) | 65.6 ± 10.9 | 31 months | 508 | 3 |
Anastrozole (10 mg/d) | 66 ± 10.4 | ||||||
Boccardo(2005) | Phase 3 trial | Early-stage breast cancer | Anastrozole (1 mg/d) | 63 (38–76) | 36 months | 223 | 4 |
Coates(2007) | Phase 3 trial | Early-stage breast cancer | Letrozole(2.5 mg/d) |  | 51 months | 2448 | 5 |
Kaufmann(2007) | Phase 3 trial | Early-stage breast cancer | Anastrozole (1 mg/d) | 60.9 mean | 30.1 months | 445 | 5 |
Coombes(2004) | Phase 3 trial | Early-stage breast cancer | Exemestane (25 mg/d) | 64.3 ± 8.1 mean SD | 30.6 months | 2362 | 4 |
Paul(2013) | Phase 3 trial | Early-stage breast cancer | Exemestane (25 mg/d) | 63.9 | 49.2 months | 7576 | 3 |
Anastrozole (1 mg/d) | 64.3 | ||||||
Baum(2003) | Phase 3 trial | Early-stage breast cancer | Anastrozole (1 mg/d) |  | 33 months | 3902 | 4 |
Joyce(2017) | Phase 3 trial | Advanced-stage breast cancer | Ribociclib + Letrozole(2.5 mg/d) | 62.5 (37.0–82.0) |  | 226 | 3 |
Letrozole(2.5 mg/d) | 63.0 (29.0–88.0) |  | |||||
Colleoni(2017) | Phase 3 trial | Early-stage breast cancer | Continuous Letrozole(2.5 mg/d) | 60 (54–67) | 60 months | 4828 | 5 |
Intermittent Letrozole(2.5 mg/d) | |||||||
Tamar(2017) | Phase 2 trial | Advanced-stage breast cancer | Everolimus(10 mg/d) plus Letrozole(2.5 mg/d) | 62.5 (34.6–82.0) | 11.4 months | 72 | 3 |
Gabe(2017) | Phase 3 trial | Advanced-stage breast cancer | Ribociclib(600 mg/d) plus Letrozole(2.5 mg/d) |  |  | 674 | 3 |
Letrozole(2.5 mg/d) |  |  |  | ||||
Vivianne(2017) | Phase 3 trial | Early-stage breast cancer | Anastrozole (1 mg/d) | 57.6 (51.2–64.5) | 50.4 months | 1660 | 5 |
Anastrozole (1 mg/d) | 57.7 (51.9–64.3) | ||||||
Smith(2017) | Phase 3 trial | Early-stage breast cancer | Letrozole(2.5 mg/d) | 62 (33–96) | 65 months | 4111 | 5 |
Anastrozole (1 mg/d) | 62 (33–92) |